Status: Recruiting
A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer
The purpose of this study is to identify the recommended phase 2 regimen(s) RP2R(s) of pasritamig and combination regimens in Part 1 (dose escalation) and to determine safety at the putative RP2R(s) of pasritamig with the combination regimens in Part 2 (dose expansion).
Participants needed: 300
Trial details
Phase: Phase 1Age: 18+Biological sex: MaleType: InterventionalSponsor: Janssen Research & Development, LLCUpdated: Sep 25, 2026Locations: 15
Eligibility criteria
Part 1 A-G, 1I, 1J, and 1K (all combination treatments) and Parts 2B-C (cabazita... [+4]
Active autoimmune disease within the 12 months prior to signing consent that req... [+4]